Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form.
about
beta-Amyloid degradation and Alzheimer's diseaseThe Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?Alzheimer's Disease: Mechanism and Approach to Cell TherapyImpaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1Effect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (review)General anesthetics and β-amyloid proteinPeripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's diseaseIn vitro Pb exposure disturbs the balance between Aβ production and elimination: the role of AβPP and neprilysinNeprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.Improved learning and memory in aged mice deficient in amyloid beta-degrading neutral endopeptidase.Mechanisms of enzymatic degradation of amyloid Beta microfibrils generating nanofilaments and nanospheres related to cytotoxicity.Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function.The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's DiseaseEnvironmental experience modulates ischemia-induced amyloidogenesis and enhances functional recovery.A neprilysin polymorphism and amyloid-beta plaques after traumatic brain injury.A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis.Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 miceAbeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species.Targeting protein aggregation for the treatment of degenerative diseases17β-estradiol and progesterone regulate expression of β-amyloid clearance factors in primary neuron cultures and female rat brainInteractions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.Neprilysin: an enzyme candidate to slow the progression of Alzheimer's diseaseExploring the contribution of estrogen to amyloid-Beta regulation: a novel multifactorial computational modeling approach.Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiationTg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy.Somatostatin receptor subtype-4 agonist NNC 26-9100 mitigates the effect of soluble Aβ(42) oligomers via a metalloproteinase-dependent mechanismNovel strategies for Alzheimer's disease treatment.The AbetaCs of Abeta-cleaving proteases.Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's DiseaseGenetic animal models of cerebral vasculopathies.Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease?Aspects of beta-amyloid as a biomarker for Alzheimer's disease.Computational insights into the development of novel therapeutic strategies for Alzheimer's disease.Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications.Proteolytic degradation of amyloid β-protein.Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease.The role of cholesterol metabolism in Alzheimer's disease.Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin.
P2860
Q21284467-FA2ABF89-2DEF-40FF-B6F9-A7EC4697EC4EQ21296650-91DFC755-F02B-48FA-9CFB-AFC35D070404Q26778149-149A2D17-CEC9-40C8-9E61-B4B28877298CQ26800063-7D0D3634-36E0-4DAC-B667-B6DACC05CB1AQ27001244-AB175499-7EEC-4295-929C-EC230F3A7024Q27010208-09DD6F2B-7DD8-44C1-8312-0DD25112D02AQ27437619-58DB8FAE-6582-4A20-A536-A78877008D02Q28388231-C2C6A08B-878C-482E-92F0-8ACF53C24D8CQ30491245-BF0DB8D5-12D9-4B28-BD29-5F728E9AE1DEQ33291757-E78C45D4-83F1-493D-B58B-33D7914BB86CQ33412126-0D340067-7274-44B4-8282-E4FB7865B959Q33536103-AAF8495E-B6AB-4CD1-A64B-2FFAF6CE0860Q33749114-43AC6375-9229-4016-BF43-1699EA81EBB5Q33755982-D4A28902-3E53-45E5-87AA-C81FEC8E6463Q33766789-59AA74AD-D6D9-4DE0-A5ED-C3F1E073ABD4Q33772447-A80BFD2F-ACA3-4E93-AEEF-F883F8ADFFB4Q33793059-1CE0DEAF-14A7-4124-B7AF-D68B2CFCC9CFQ34476355-62DD186F-63DF-4B8B-9F6C-14CDE71893F5Q34516687-9CE3D434-B19D-4AF4-874F-EA14E9FD74C6Q34624507-A8B5AB6C-15BA-4EEB-81A4-AF9C73D800EEQ36235980-D049B8F3-1FCC-4569-ADD8-1BD582A9F559Q36323138-D6B3DD56-75AC-4847-8E53-DBF726B6C8C7Q36576477-7CE90457-06F8-4786-85FC-413F5D0B378AQ36579852-7DCCE5FA-70CA-46FC-B112-267127585BB3Q36648823-44005F43-D988-4DDD-A67B-AEB3A6194414Q36711191-7A72AAF7-3D27-4C94-85DA-41D7ECF4CAD9Q36778265-AADF23AF-6A15-4157-B1A1-651C5577945CQ36941069-CB941B9F-27CC-4274-8A60-DDFAEA30C1E2Q37012066-4AA02CA4-3BD8-4BFC-91A9-26F4539603C0Q37250796-694E3B7C-15A0-4917-859B-9D741DFC2A52Q37408544-C7888AA3-C74D-4E0E-B552-FAF1A758A56FQ37542635-E21952CC-3E39-4A60-A037-9039FE1681E2Q37691554-20C847B2-6658-4D9F-8286-7E9D37AF8CA8Q37755129-271340A2-588B-452A-BA34-E6666818DB6FQ37855869-ABFDF89C-754C-4B01-A082-BDF62ECC6108Q37960498-755198D1-FEEC-4580-AF04-059C494388AFQ38016899-DC6474B6-3CB2-4478-9015-D367657613C7Q38123911-11B9725B-95AD-4097-93C5-F79F253D0A8EQ38212604-58BCAC20-9E3D-46E5-A49D-4F8B78A4AE6AQ38257065-21D225A3-FD71-49DB-84D6-AA3D4A8ACB3C
P2860
Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Human neprilysin is capable of ...... pathological oligomeric form.
@en
type
label
Human neprilysin is capable of ...... pathological oligomeric form.
@en
prefLabel
Human neprilysin is capable of ...... pathological oligomeric form.
@en
P2093
P1433
P1476
Human neprilysin is capable of ...... pathological oligomeric form.
@en
P2093
Hiroshi Mori
Hyoe Kanemitsu
Takami Tomiyama
P304
P356
10.1016/S0304-3940(03)00898-X
P407
P577
2003-10-01T00:00:00Z